Seventy-four percent of biologic-naive patients with Crohn’s disease reached clinical remission at week 12 on subcutaneous risankizumab, compared with 27 percent on placebo. That number, from the Phase 3 AFFIRM trial, is what the FDA cited when it approved AbbVie’s subcutaneous induction regimen for SKYRIZI on October 23, giving patients the option to start treatment at home rather than in an infusion center.
The approval adds a self-administered induction option to a drug that previously required IV infusion to start. Patients now receive 720 mg by on-body injector at weeks 0, 2, 4, and 8, then continue the same device every eight weeks through maintenance. The IV path remains available. In the advanced therapy-naive group, endoscopic response reached 60 percent versus 15 percent for placebo, four times the placebo rate. In patients who had already failed a biologic or JAK inhibitor, remission rates were lower but still favored the drug: 45 percent versus 31 percent on placebo.
What the trial design reveals matters for future studies. AFFIRM enrolled a primarily treatment-refractory population, which makes the naive-patient numbers even sharper in contrast: the gap between prior-failure and naive responders is wide, and AbbVie has noted those subcutaneous results as a foundation for additional clinical programs. The safety profile matched what has been observed with intravenous SKYRIZI in Crohn’s, with no new risks identified. The FDA also revised the SKYRIZI label across all its approved indications to let clinicians use their own judgment on whether to conduct tuberculosis testing before treatment, rather than requiring it by default.
For clinical operations teams running Crohn’s trials, the practical consequence is that a fully subcutaneous induction-to-maintenance sequence is now an approved reference standard in this disease. Trial designs proposing IV induction for an IL-23 agent will face harder questions from investigators and IRBs about patient convenience relative to this new benchmark. The number to watch in the near term is the real-world remission rate in biologic-naive patients outside a controlled trial, where AFFIRM’s 74 percent will be the comparison point.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
